<DOC>
	<DOCNO>NCT01363908</DOCNO>
	<brief_summary>This open-label study ass pharmacokinetics , safety , efficacy tolerability SSP-004184AQ . The study consist two phase : pharmacokinetic phase , use single 16 mg/kg dose SSP-004184AQ ; chronic dosing phase , patient receive additional 48 week SSP-004184AQ dose . Two age group study : 6- &lt; 12 , 12- &lt; 18 year old . The study design initially assess pharmacokinetics safety SSP-004184AQ old child ( adolescent , 12- &lt; 18 year old ) deem safe , young child ( 6- &lt; 12 year old ) .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics Oral Iron Chelator Given Year Pediatric Patients With Iron Overload</brief_title>
	<detailed_description>Pharmacokinetic Phase : Patients receive single 16 mg/kg dose SSP-004184AQ capsule form . Chronic Dosing Phase : Patients receive SSP-004184AQ capsule daily 48 week . Doses may range 8-60 mg/kg/d .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Inclusion Criteria Parents willing able sign approve informed consent child subject age 6 &lt; 18 year willing able provide assent ( base institutional guideline ) . Able swallow whole capsule . Age &gt; 6 &lt; 18 year . Transfusiondependent subject transfusional iron overload require chronic treatment deferoxamine , deferasirox , deferiprone . A transfusion dependent subject define study one minimum transfusion history total 20 unit pack red blood cell OR calculate iron load base transfusion history 200mg/kg AND transfusion requirement 7 transfusion per year ; , subject sickle cell anemia , iron overload receive transfusion exchange therapy lieu transfusion . In opinion Investigator ( consultation subject 's parent ) , subject able discontinue exist iron chelation therapy minimum period 15 day prior first dose SSP004184AQ , initial pharmacokinetic period 8 day ( applicable ) , 49 week continue chronic dose phase . Subjects able MRI must : 1. liver iron concentration &gt; 2 &lt; 30mg/g ( dry weight , liver ) FerriScan® R2 2. cardiac MRI T2* &gt; 10ms ( Note : Subjects able MRI consider iron overload basis serum ferritin . ) Serum ferritin &gt; 500ng/mL Screening . Mean previous 3 pretransfusion hemoglobin concentration great equal 7.5g/dL . If appropriate , depend age , female subject childbearing potential need use medically acceptable method birth control screen 30 day last dose study drug . Females childbearing potential must negative serum betaHCG pregnancy test Screening Visit negative urine pregnancy test Baseline Visit . Females childbearing potential must agree abstain sexual activity could result pregnancy agree use acceptable method contraception . Exclusion Criteria As result medical review , physical examination ( include height weight ) Screening investigation , Principal Investigator considers subject unfit study . Iron overload cause transfusional hemosiderosis . Severe cardiac dysfunction . Nonelective hospitalization within 30 day prior Baseline test . Evidence clinically significant oral , cardiovascular , gastrointestinal , hepatic , biliary , renal , endocrine , pulmonary , neurologic , psychiatric , skin disorder contraindicates dose SSP004184AQ . Evidence significant renal insufficiency , eg , serum creatinine upper limit normal proteinuria great 1 gm per day . Known sensitivity ingredient SSP004184AQ formulation . Platelet count 100,000/µL absolute neutrophil count le 1500/mm3 Screening . ALT &gt; 180 IU/L Screening . Use investigational agent within 30 day prior Baseline test . Pregnant lactating female . Cardiac leave ventricular ejection fraction ) Below locally determine normal range 12 month prior screen echocardiography MRI &lt; 50 % Baseline testing MRI ( echocardiograph acceptable LVEF MRI information available ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Beta-Thalassemia</keyword>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Transfusional iron overload</keyword>
	<keyword>Iron Overload</keyword>
	<keyword>Iron Chelation</keyword>
</DOC>